FDA approves InSightec's ultrasound-based ExAblate pain treatment system

Tue, 10/23/2012 - 1:38pm
Mass Device

Israeli device maker InSightec lands FDA approval to treat painful bone metastases with its ExAblate ultrasound-based therapy.

Insightec's ExAblate system

Israeli device maker InSightec won FDA approval for its ExAblate MRI-guided focused ultrasound therapy with indication to treat pain resulting from bone metastases in patients who failed or aren't good candidates for radiation therapy.

Bone metastases occur when cancer cells break off from the primary tumor site and spread to other parts of the body, commonly leaving patients with significant physical and emotional pain, according to a press release.

More than ⅔ of breast and prostate cancers that metastasize spread to the bones, according to the American Cancer Society, and 1 out of 3 of bone metastases patients either do no respond to radiation therapy or aren't able to receive radiation treatment.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.